May 8, 2026 WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it has priced a private placement with accredited investors for aggregate gross proceeds of approximately $2.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 488,281 shares of common stock (the “Shares”) at a purchase price of $5.12 per Share. In lieu of Shares that would otherwise result in a purchaser’s beneficial ownership exceeding 4.99% of the outstanding common stock, certain purchasers may elect to receive pre-funded warrants...

Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) — HIGHLIGHTSAmplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapy Ovarian cancer represents a major target for FAK inhibition therapy based on typically higher levels of FAK expression and fibrous nature of tumour The study to enrol patients with high-grade serous ovarian cancer (HGSOC) who have not responded to platinum-based chemotherapy prior to surgery Study focus is safety and exploring potential to improve post-surgical outcomes; biomarker collection will further characterize mechanism of action of narmafotinib{{DATELINECITY_DATE_GLOBENEWSWIRE_BUG}Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), and the Australia New Zealand Gynaecological...

ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA.   Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.   LD Micro Invitational XVI Conference Details: Date: Monday, May 18, 2026 Company Presentation: 10:30 am PT Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Webcast:   Click for Link For more information or to attend the conference, click here. About electroCore, Inc.electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic...

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Lumentum Holdings Inc. (Nasdaq: LITE) will become a component of the Nasdaq-100 Index® replacing CoStar Group, Inc. (Nasdaq: CSGP) prior to market open on Monday, May 18, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world’s leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Index® — which measures the performance of 100 of the largest Nasdaq-listed non-financial companies — is tracked by more than 200 investment products with over $600 billion in assets under management globally. Nasdaq Global Indexes publishes and maintains more than...

ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes an audit opinion from HTL International LLC. that contains a “going concern” qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company’s financial statements for the year ended December 31, 2025. Again, this announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025. About DSS, Inc. DSS, Inc. (NYSE American:...

MONTRÉAL, May 08, 2026 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Company” or “Premier Health”), a leading Canadian health tech company, announced that as previously disclosed in its most recent MD&A for the quarter ended December 31, 2025, the Company was in default of financial ratios under its credit agreements. As such, on April 24, 2025, the Company signed a Forbearance agreement with its lenders. Under this agreement, the lenders agreed to tolerate the defaults so long as the Company abides by certain rules and conditions. The Forbearance Agreement was terminated on April 10, 2026. Since then, the Company and its lenders are actively engaged in discussions to resolve the situation. In parallel, the Company continues to be actively engaged in further discussions with potential partners and strategic...

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients treated with VYVGART in the ADAPT SERON study experienced rapid, significant and sustained symptom improvements that continued with ongoing treatment Approval advances argenx’s commitment to address the unique needs of every MG patient, delivering the broadest MG label to dateMay 8, 2026, 5:20 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for VYVGART® (efgartigimod alfa-fcab) and...